| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Crispr Therapeutics AG (CRSP) has 7 insiders with recent SEC Form 4 filings, including 0 buys and 26 sells. CRSP is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 255.5K | $13.89M | - | |
| Dir | 22.0K | $1.20M | - | |
| CFO | 19.5K | $1.06M | - | |
| Other | 19.4K | $1.05M | -3,786 | |
| Other | 17.0K | $924.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 5, 2017 | Novak Rodger75 | Chief Executive Officer | Sale+OE | 616 | $16.92 | $10,425.68 | - | |
| May 4, 2017 | Novak Rodger75 | Chief Executive Officer | Sale+OE | 49,384 | $16.30 | $805,183.12 | -1.0% | |
| May 1, 2017 | Dylan-Hyde Tyler | Chief Legal Officer | Sell | 1,852 | $16.61 | $30,753.39 | -1.1% | |
| Apr 28, 2017 | Dylan-Hyde Tyler | Chief Legal Officer | Sell | 21,639 | $16.78 | $363,077.31 | -4.0% | |
| Apr 27, 2017 | Kulkarni Samarth68 | Chief Business Officer | Sale+OE | 5,481 | $16.76 | $91,839.15 | -2.0% | |
| Apr 25, 2017 | Kulkarni Samarth68 | Chief Business Officer | Sale+OE | 11,615 | $16.78 | $194,942.20 | -2.8% | |
| Apr 25, 2017 | Dylan-Hyde Tyler | Chief Legal Officer | Sell | 11,332 | $16.78 | $190,109.40 | -2.0% | |
| Apr 20, 2017 | Novak Rodger75 | Chief Executive Officer | Sale+OE | 50,000 | $17.88 | $893,917.96 | -1.3% | |
| Apr 20, 2017 | Kulkarni Samarth68 | Chief Business Officer | Sale+OE | 10,058 | $17.73 | $178,375.51 | -2.4% | |
| Apr 20, 2017 | Dylan-Hyde Tyler | Chief Legal Officer | Sell | 10,177 | $17.71 | $180,190.09 | -1.7% |